In 1818, the idea of extending life by borrowing body parts was a cutting-edge fictional prospect, but now it’s a daily ...
Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, ...
CAR2119’s single-infusion approach offers cost and compliance advantages, though its competitors maintain strong commercial ...
(NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in ...
After a decade of work, researchers are closer than ever to a key breakthrough in kidney organ transplants - being able to ...
mRNA-4359 combined with pembrolizumab achieved a 24% ORR and 67% efficacy in PD-L1 positive melanoma patients. The study ...
Researchers report the first human test of an enzyme-converted A-type kidney to universal O, which if validated in future ...
Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with ...
UT Southwestern Medical Center researchers have identified two distinct populations of cells known as antigen-presenting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback